These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22209496)

  • 1. Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study.
    Moodie J; Healy BC; Buckle GJ; Gauthier SA; Glanz BI; Arora A; Ceccarelli A; Tauhid S; Han XM; Venkataraman A; Chitnis T; Khoury SJ; Guttmann CR; Weiner HL; Neema M; Bakshi R
    J Neurol Sci; 2012 Apr; 315(1-2):49-54. PubMed ID: 22209496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale.
    Bakshi R; Neema M; Healy BC; Liptak Z; Betensky RA; Buckle GJ; Gauthier SA; Stankiewicz J; Meier D; Egorova S; Arora A; Guss ZD; Glanz B; Khoury SJ; Guttmann CR; Weiner HL
    Arch Neurol; 2008 Nov; 65(11):1449-53. PubMed ID: 19001162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis.
    Kim G; Tauhid S; Dupuy SL; Tummala S; Khalid F; Healy BC; Bakshi R
    J Neurol; 2016 Mar; 263(3):531-8. PubMed ID: 26754005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis.
    Tauhid S; Neema M; Healy BC; Weiner HL; Bakshi R
    J Neurol Sci; 2014 Nov; 346(1-2):250-4. PubMed ID: 25220114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2.
    Bakshi R; Neema M; Tauhid S; Healy BC; Glanz BI; Kim G; Miller J; Berkowitz JL; Bove R; Houtchens MK; Severson C; Stankiewicz JM; Stazzone L; Chitnis T; Guttmann CR; Weiner HL; Ceccarelli A
    Neuroreport; 2014 Oct; 25(14):1156-61. PubMed ID: 25100554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Contribution of Cortical Lesions to a Composite MRI Scale of Disease Severity in Multiple Sclerosis.
    Yousuf F; Kim G; Tauhid S; Glanz BI; Chu R; Tummala S; Healy BC; Bakshi R
    Front Neurol; 2016; 7():99. PubMed ID: 27445966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A semiautomated measure of whole-brain atrophy in multiple sclerosis.
    Bermel RA; Sharma J; Tjoa CW; Puli SR; Bakshi R
    J Neurol Sci; 2003 Apr; 208(1-2):57-65. PubMed ID: 12639726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes.
    Bose G; Healy BC; Saxena S; Saleh F; Paul A; Barro C; Lokhande HA; Polgar-Turcsanyi M; Anderson M; Glanz BI; Guttmann CRG; Bakshi R; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2023 Jun; 74():104695. PubMed ID: 37060852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis.
    Tauhid S; Chu R; Sasane R; Glanz BI; Neema M; Miller JR; Kim G; Signorovitch JE; Healy BC; Chitnis T; Weiner HL; Bakshi R
    J Neurol; 2015 Nov; 262(11):2425-32. PubMed ID: 26205635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications.
    Fox RJ; Fisher E; Tkach J; Lee JC; Cohen JA; Rudick RA
    Mult Scler; 2005 Apr; 11(2):140-5. PubMed ID: 15794385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative MRI analysis of cerebral lesions and atrophy in post-partum patients with multiple sclerosis.
    Khalid F; Healy BC; Dupuy SL; Chu R; Chitnis T; Bakshi R; Houtchens M
    J Neurol Sci; 2018 Sep; 392():94-99. PubMed ID: 30031994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain MRI Predicts Worsening Multiple Sclerosis Disability over 5 Years in the SUMMIT Study.
    Bakshi R; Healy BC; Dupuy SL; Kirkish G; Khalid F; Gundel T; Asteggiano C; Yousuf F; Alexander A; Hauser SL; Weiner HL; Henry RG;
    J Neuroimaging; 2020 Mar; 30(2):212-218. PubMed ID: 31994814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity.
    Regev K; Healy BC; Khalid F; Paul A; Chu R; Tauhid S; Tummala S; Diaz-Cruz C; Raheja R; Mazzola MA; von Glehn F; Kivisakk P; Dupuy SL; Kim G; Chitnis T; Weiner HL; Gandhi R; Bakshi R
    JAMA Neurol; 2017 Mar; 74(3):275-285. PubMed ID: 28114622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis.
    Zivadinov R; Uxa L; Bratina A; Bosco A; Srinivasaraghavan B; Minagar A; Ukmar M; Benedetto Sy; Zorzon M
    Int Rev Neurobiol; 2007; 79():521-35. PubMed ID: 17531857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI phenotypes in MS: Longitudinal changes and miRNA signatures.
    Hemond CC; Healy BC; Tauhid S; Mazzola MA; Quintana FJ; Gandhi R; Weiner HL; Bakshi R
    Neurol Neuroimmunol Neuroinflamm; 2019 Mar; 6(2):e530. PubMed ID: 30800720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-brain atrophy assessed by proportional- versus registration-based pipelines from 3T MRI in multiple sclerosis.
    Hemond CC; Chu R; Tummala S; Tauhid S; Healy BC; Bakshi R
    Brain Behav; 2018 Aug; 8(8):e01068. PubMed ID: 30019857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis.
    Tavazzi E; Bergsland N; Kuhle J; Jakimovski D; Ramanathan M; Maceski AM; Tomic D; Hagemeier J; Kropshofer H; Leppert D; Dwyer MG; Weinstock-Guttman B; Benedict RHB; Zivadinov R
    J Neurol; 2020 Mar; 267(3):802-811. PubMed ID: 31768628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis.
    Calabrese M; Rocca MA; Atzori M; Mattisi I; Favaretto A; Perini P; Gallo P; Filippi M
    Ann Neurol; 2010 Mar; 67(3):376-83. PubMed ID: 20373349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative diffusion weighted imaging measures in patients with multiple sclerosis.
    Tavazzi E; Dwyer MG; Weinstock-Guttman B; Lema J; Bastianello S; Bergamaschi R; Cosi V; Benedict RH; Munschauer FE; Zivadinov R
    Neuroimage; 2007 Jul; 36(3):746-54. PubMed ID: 17498974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.